These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17482306)

  • 21. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Update on new insulins].
    Philips JC; Radermecker R
    Rev Med Suisse; 2005 Aug; 1(30):1936-8, 1940-1. PubMed ID: 16200936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The new insulins.
    Crotty S; Reynolds SL
    Pediatr Emerg Care; 2007 Dec; 23(12):903-5; quiz 906-7. PubMed ID: 18091602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The use of artificial beta-cells or programmed insulin infusions in the therapy of insulin-dependent diabetes mellitus].
    Bruns W; Fischer U
    Z Gesamte Inn Med; 1981 Sep; 36(17):625-7. PubMed ID: 7048769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic insulins and their large-scale manufacture.
    Walsh G
    Appl Microbiol Biotechnol; 2005 Apr; 67(2):151-9. PubMed ID: 15580495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative routes and methods of insulin delivery.
    Home PD; Gill GV; Husband D; Kruszynska YT; Marshall S; Alberti KG
    Neth J Med; 1985; 28 Suppl 1():32-6. PubMed ID: 3925355
    [No Abstract]   [Full Text] [Related]  

  • 28. Monomeric insulins obtained by protein engineering and their medical implications.
    Brange J; Ribel U; Hansen JF; Dodson G; Hansen MT; Havelund S; Melberg SG; Norris F; Norris K; Snel L
    Nature; 1988 Jun; 333(6174):679-82. PubMed ID: 3287182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current trends in insulin therapy].
    Pelikánová T
    Vnitr Lek; 2002 Jun; 48(6):523-8. PubMed ID: 12132354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in insulin treatment of children.
    Steck AK; Klingensmith GJ; Fiallo-Scharer R
    Pediatr Diabetes; 2007 Oct; 8 Suppl 6():49-56. PubMed ID: 17727385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human insulin.
    Raptis S; Dimitriadis G
    Clin Physiol Biochem; 1985; 3(1):29-42. PubMed ID: 3888492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The INCA system: a further step towards a telemedical artificial pancreas.
    Gómez EJ; Hernando Pérez ME; Vering T; Rigla Cros M; Bott O; García-Sáez G; Pretschner P; Brugués E; Schnell O; Patte C; Bergmann J; Dudde R; de Leiva A
    IEEE Trans Inf Technol Biomed; 2008 Jul; 12(4):470-9. PubMed ID: 18632327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.
    Bruttomesso D; Costa S; Baritussio A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):99-111. PubMed ID: 19172576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of oral insulin delivery systems.
    Wong TW
    J Drug Target; 2010 Feb; 18(2):79-92. PubMed ID: 19968567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Are des-Phe-insulin-containing insulin combinations preferable to regular trade preparations?].
    Sachse G; Federlin K
    Med Klin; 1981 May; 76(11):319-23. PubMed ID: 7017364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy.
    Shalitin S; Phillip M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S121-4. PubMed ID: 18227471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.